Show simple item record

dc.contributor.authorKalamarides, Michel
dc.contributor.authorAcosta, Maria T.
dc.contributor.authorBabovic-Vuksanovic, Dusica
dc.contributor.authorCarpen, Olli
dc.contributor.authorGareth Evans, D.
dc.contributor.authorGiancotti, Filippo
dc.contributor.authorOliver Hanemann, C.
dc.contributor.authorIngram, David
dc.contributor.authorLloyd, Alison C.
dc.contributor.authorMayes, Debra A.
dc.contributor.authorMessiaen, Ludwine
dc.contributor.authorMorrison, Helen
dc.contributor.authorNorth, Kathryn
dc.contributor.authorPacker, Roger
dc.contributor.authorPan, Duojia
dc.contributor.authorUpadhyaya, Meena
dc.contributor.authorViskochil, David
dc.contributor.authorWallace, Margret R.
dc.contributor.authorHunter-Schaedle, Kim
dc.contributor.authorRatner, Nancy
dc.contributor.authorCichowski, Karen Marie
dc.contributor.authorStemmer-Rachamimov, Anat
dc.date.accessioned2012-05-22T15:41:44Z
dc.date.issued2012
dc.identifier.citationKalamarides, Michel, Maria T. Acosta, Dusica Babovic-Vuksanovic, Olli Carpen, Karen Cichowski, D. Gareth Evans, Filippo Giancotti, et al. 2012. Neurofibromatosis 2011: A report of the children’s tumor foundation annual meeting. Acta Neuropathologica 123(3): 369-380.en_US
dc.identifier.issn0001-6322en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8792617
dc.description.abstractThe 2011 annual meeting of the Children’s Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.en_US
dc.language.isoen_USen_US
dc.publisherSpringer-Verlagen_US
dc.relation.isversionofdoi:10.1007/s00401-011-0905-0en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282898/pdf/en_US
dash.licenseLAA
dc.titleNeurofibromatosis 2011: A Report of the Children’s Tumor Foundation Annual Meetingen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalActa Neuropathologicaen_US
dash.depositing.authorCichowski, Karen Marie
dc.date.available2012-05-22T15:41:44Z
dc.identifier.doi10.1007/s00401-011-0905-0*
dash.authorsorderedfalse
dash.contributor.affiliatedCichowski, Karen
dash.contributor.affiliatedStemmer-Rachamimov, Anat


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record